Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
Rhea-AI Summary
Quantum BioPharma (NASDAQ: QNTM) said a U.S. District Court in the Southern District of New York largely denied CIBC World Markets and RBC Dominion Securities' joint motion to dismiss a USD $700,000,000 lawsuit alleging market manipulation.
The suit alleges spoofing between Jan 1, 2020 and Aug 15, 2024 and cites Section 10(b), Rule 10b-5(a) and (c), and Section 9(a) of the Securities Exchange Act.
Positive
- Court denial of defendants' motion to dismiss allows the lawsuit to proceed
- $700,000,000 claim linked to alleged spoofing from Jan 1, 2020 to Aug 15, 2024
Negative
- Lawsuit names major financial firms CIBC and RBC
- Allegations invoke federal securities statutes: Section 10(b), Rule 10b-5, Section 9(a)
News Market Reaction – QNTM
In the Apr 2 session, QNTM declined 9.75%, reflecting a notable negative market reaction. Argus tracked a peak move of +8.2% during that session. Argus tracked a trough of -19.9% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | IND submission | Positive | -8.7% | Filed FDA IND for Lucid-MS Phase 2 in multiple sclerosis. |
| Mar 30 | Trial support LOI | Positive | -10.3% | Signed LOI with Allucent to run Lucid-MS Phase 2 trial. |
| Mar 27 | Year-end results | Positive | +24.5% | 2025 audited results maintained company’s ‘no going concern’ status. |
| Mar 26 | PI appointment | Positive | -11.9% | Named principal investigator for planned Lucid-MS Phase 2 study. |
| Mar 23 | Clinical publication | Positive | +38.4% | Peer-reviewed trial showed unbuzzd improved alcohol clearance and symptoms. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and strategic updates often saw negative price reactions, with 3 of the last 5 events diverging from their broadly positive tone.
Over late March and early April 2026, Quantum BioPharma reported several milestones: a peer‑reviewed trial publication for unbuzzd with strong efficacy data, appointment of a principal investigator, a Phase 2 support LOI, and an IND submission for Lucid‑MS, plus audited 2025 results maintaining “no going concern” status. Price reactions were mixed: clinical and operational positives on Mar 26–30 and Apr 1 coincided with declines, while the unbuzzd publication on Mar 23 and earnings on Mar 27 aligned with strong gains.
Key Terms
spoofing technical
Section 10(b) regulatory
Rule 10b-5 regulatory
market manipulation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has largely ruled against defendants CIBC World Markets (“CIBC”) and RBC Dominion Securities (“RBC”) joint motion to dismiss Quantum Biopharma’s lawsuit alleging illegal market manipulation.
The Quantum Biopharma lawsuit alleges that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum BioPharma shares. The Company alleges that these market manipulation schemes violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934.
The full text of the Court’s ruling can be found here: District Court Opinion & Order
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (416) 854-8884
Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com
